Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37942534)

  • 21. Differential DNA methylation analysis of
    Su JQ; Lai PY; Hu PH; Hu JM; Chang PK; Chen CY; Wu JJ; Lin YJ; Sun CA; Yang T; Hsu CH; Lin HC; Chou YC
    World J Gastroenterol; 2022 Feb; 28(8):825-839. PubMed ID: 35317099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array.
    Lin PC; Lin JK; Lin CH; Lin HH; Yang SH; Jiang JK; Chen WS; Chou CC; Tsai SF; Chang SC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1419-27. PubMed ID: 25472652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of BMP6 is associated with its methylation status in colorectal cancer tissue but lacks prognostic significance.
    Sangplod P; Kanngurn S; Boonpipattanapong T; Ruangrat P; Sangkhathat S
    Asian Pac J Cancer Prev; 2014; 15(17):7091-5. PubMed ID: 25227796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
    Cheetham S; Tang MJ; Mesak F; Kennecke H; Owen D; Tai IT
    Br J Cancer; 2008 Jun; 98(11):1810-9. PubMed ID: 18458674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
    Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
    Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping of DNA Hypermethylation and Hypomethylation induced by Folate Deficiency in Sporadic Colorectal Cancer and Clinical Implication Analysis of Hypermethylation Pattern in CBS Promoter.
    Zhang Z; He Y; Tu X; Huang S; Chen Z; Wang L; Song J
    Clin Lab; 2017 Apr; 63(4):733-748. PubMed ID: 28397458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
    Renaud F; Vincent A; Mariette C; Crépin M; Stechly L; Truant S; Copin MC; Porchet N; Leteurtre E; Van Seuningen I; Buisine MP
    Int J Cancer; 2015 Jun; 136(12):2811-21. PubMed ID: 25403854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
    Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
    PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEACAM5 inhibits the lymphatic metastasis of head and neck squamous cell carcinoma by regulating epithelial-mesenchymal transition via inhibiting MDM2.
    Wang X; Li Y; Pan M; Lu T; Wang M; Wang Z; Liu C; Hu G
    Clin Sci (Lond); 2022 Nov; 136(22):1691-1710. PubMed ID: 36377775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promoter methylation and expression of SOCS-1 affect clinical outcome and epithelial-mesenchymal transition in colorectal cancer.
    Kang XC; Chen ML; Yang F; Gao BQ; Yang QH; Zheng WW; Hao S
    Biomed Pharmacother; 2016 May; 80():23-29. PubMed ID: 27133036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semaphorin-3F functions as a tumor suppressor in colorectal cancer due to regulation by DNA methylation.
    Gao X; Tang C; Shi W; Feng S; Qin W; Jiang T; Sun Y
    Int J Clin Exp Pathol; 2015; 8(10):12766-74. PubMed ID: 26722466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer.
    Rawluszko AA; Bujnicka KE; Horbacka K; Krokowicz P; Jagodziński PP
    BMC Cancer; 2013 Nov; 13():526. PubMed ID: 24195777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential regulation of CpG island methylation within divergent and unidirectional promoters in colorectal cancer.
    Namba S; Sato K; Kojima S; Ueno T; Yamamoto Y; Tanaka Y; Inoue S; Nagae G; Iinuma H; Hazama S; Ishihara S; Aburatani H; Mano H; Kawazu M
    Cancer Sci; 2019 Mar; 110(3):1096-1104. PubMed ID: 30637877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.
    Alizadeh Naini M; Kavousipour S; Hasanzarini M; Nasrollah A; Monabati A; Mokarram P
    Asian Pac J Cancer Prev; 2018 May; 19(5):1223-1227. PubMed ID: 29801405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.
    Wang Y; He T; Herman JG; Linghu E; Yang Y; Fuks F; Zhou F; Song L; Guo M
    Clin Epigenetics; 2017; 9():115. PubMed ID: 29075358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
    Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
    PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells.
    Gisina A; Novikova S; Kim Y; Sidorov D; Bykasov S; Volchenko N; Kaprin A; Zgoda V; Yarygin K; Lupatov A
    Cancer Biomark; 2021; 32(1):85-98. PubMed ID: 34092615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylation status of T-lymphoma invasion and metastasis 1 promoter and its overexpression in colorectal cancer.
    Jin H; Li T; Ding Y; Deng Y; Zhang W; Yang H; Zhou J; Liu C; Lin J; Ding Y
    Hum Pathol; 2011 Apr; 42(4):541-51. PubMed ID: 21237486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Wang XM; Zhang Z; Pan LH; Cao XC; Xiao C
    Breast Cancer Res Treat; 2019 Apr; 174(2):375-385. PubMed ID: 30535933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.